Ally Bridge Group’s Definium Therapeutics DFTX Stock Holding History

Ally Bridge Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-361,444	Closed	-$4.26M	–	26
2025 Q3	$4.26M	Sell	361,444 -364,728	-50%	-$3.4M	2.6%	16
2025 Q2	$4.71M	Buy	726,172 +336,029	+86%	+$2.21M	3.92%	11
2025 Q1	$2.28M	Buy	390,143 +59,868	+18%	+$429K	2.06%	19
2024 Q4	$2.3M	Sell	330,275 -458,233	-58%	-$3.15M	1.97%	25
2024 Q3	$4.49M	Sell	788,508 -176,918	-18%	-$1.23M	2.4%	23
2024 Q2	$6.96M	Sell	965,426 -36,026	-4%	-$315K	4.15%	11
2024 Q1	$9.41M	Buy	+1,001,452	New	+$5.71M	5.23%	8

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ally Bridge Group's DFTX Position: Q4 2025 in Review

Ally Bridge Group sold out of Definium Therapeutics (DFTX) in Q4 2025, closing a stake of 361,444 shares — an estimated $4.26M sold.

Ally Bridge Group first reported a position in DFTX in Q1 2024 and held it in 7 quarters. The position peaked at $9.41M in Q1 2024. 208 funds tracked by Wall St. Rank hold DFTX as of Q4 2025.

Ally Bridge Group reported no remaining Definium Therapeutics position as of Q4 2025 after selling out during the quarter.
Ally Bridge Group sold 361,444 Definium Therapeutics shares in Q4 2025, an estimated $4.26M.
Ally Bridge Group first reported a position in Definium Therapeutics in Q1 2024 and held it in 7 quarters.
Ally Bridge Group's Definium Therapeutics position peaked at $9.41M in Q1 2024.
208 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2025.

Based on Ally Bridge Group's 13F filing for Q4 2025, filed 17 Feb 2026.